Volume 27, Number 12—December 2021
Research Letter
Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine
Abstract
In vitro determination of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies induced in serum samples from recipients of the CoronaVac vaccine showed a short protection period against the original virus strain and limited protection against variants of concern. These data provide support for vaccine boosters, especially variants of concern circulate.
Circulation of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants capable of evading vaccine-derived protection is challenging the efficacy of coronavirus disease (COVID-19) vaccines (1). The inactivated SARS-CoV-2 vaccine CoronaVac (Sinovac Biotech, http://www.sinovac.com), 1 of 2 COVID-19 vaccines licensed in Thailand, has been widely administered to health care workers. Clinical studies show CoronaVac efficacy against symptomatic COVID-19 ranging from 51% (Brazil) to 65.9% (Chile) and 100% against severe illness and illness requiring hospitalization (2,3). However, data on CoronaVac efficacy against variants of concern are very limited. Our study was approved by the Research Ethics Review Committee, Faculty of Medicine, Chulalongkorn University (Bangkok, Thailand) and recorded in the Thai Clinical Trial Registry (TCTR20210325003). Investigators adhered to U.S. Department of Defense AR 70–25 policies for protection of human subjects.
For this study, we enrolled 207 health care workers in Thailand who were fully vaccinated with 2 doses of CoronaVac (0.5 mL/dose, 2–4 wk between doses); all had received their first dose during February 22–March 12, 2021. Median age was 39 (interquartile range 30–51) years of age; 103 (49.6%) were men. Among study participants, 58 (28%) provided blood samples only at baseline (when the first dose was administered), 93 (44.0%) both at baseline and 2–3 weeks after the second dose, and 56 (27.0%) at baseline and at 2–3 weeks and 10–12 weeks after the second dose. Using an in vitro system (Appendix), we evaluated the ability of the serum of CoronaVac recipients to neutralize SARS-CoV-2. We measured circulating serum neutralizing antibodies to the original wild-type strain by using a cPass receptor binding domain antigen-based surrogate virus neutralization test (sVNT) ELISA (GeneScript, https://www.genscript.com) (4) and using a microneutralization assay (MNA) (5) for SARS-CoV-2 Wild-type strain and Alpha, Beta, and Delta neutralizing antibodies. Seroconversion rates for CoronaVac-vaccinated participants, determined by sVNT ELISA using 30% inhibition as cutoff, were 85.2% (78.2% mean inhibition level) at 2–3 weeks and 35% (25.4% mean inhibition level) at 10–12 weeks. The MNA seropositivity cutoff was set at ≥50%.
Figure
Figure. Results of in vitro testing by microneutralization assay of CoronaVac-induced neutralizing A) Wild-type strain and B) Alpha-, C) Beta-, and D) Delta-variant SARS-CoV-2 antibodies (n = 207). Overall vaccine-induced neutralizing...
At 2–3 weeks after the second dose, 61.1% (91/149) of participants were seropositive against the Wild-type strain, 35.6% (53/149) against Alpha variant, 3.4% (5/149) against Beta, and 8.7% (13/149) against Delta (Figure). Mean neutralizing rate at 2–3 weeks was 49.3% (95% CI 44.9%–53.6%) against Wild-type strain, 40.9% (95% CI 37.8%–43.9%) against Alpha variant, 9.0% (95% CI 6.1%–11.8%) against Beta, and 10.8% (95% CI 7.1%–14.5%) against Delta. At 10–12 weeks after the second dose, the proportion of seropositive participants fell to 50% (28/56) against Wild-type strain and was significantly reduced (p < 0.001) to 17.9% (10/56) against Alpha variant, 1.8% (1/56) against Beta, and 1.8% (1/56) against Delta. Mean neutralizing rates at 10–12 weeks were 48.0% (95% CI 39.9%–56.1%) against Wild-type strain, 21.8% (95% CI 37.8%–43.9%) against Alpha variant, 1.2% (95% CI 3.5%–8.8%) against Beta, and 1.0% (95% CI 2.9%–7.5%) against Delta.
Comparing sVNT ELISA results between the 2 time points, Wild-type strain antibodies appear to have a half-life of 83.4 days (95% CI 76.6–90.3 days). However, when the MNA was used, neutralizing antibodies waned in a time- and variant-dependent manner. The half-life of neutralizing antibodies was as low as 47.2 days (95% CI 37.5–56.9 days) for Wild-type strain, 38.6 days (95% CI 31.2–45.9 days) for Alpha variant, 6.9 days (95% CI 3.2–10.6 days) for Beta, and 12.3 days (95% CI 6.8–17.8 days) for Delta (Table). These data indicate the possibility that SARS-CoV-2 variants are able to escape humoral induced by wild-type prototype inactivated vaccines, which is consistent with results of other recent studies (4,5). Our findings support administering vaccine boosters, especially where these variants circulate.
Dr. Hunsawong is a research scientist in the Department of Virology of the US Army Medical Directorate of the Armed Forces Research Institute of Medical Sciences in Bangkok, Thailand. Her research interests include host-immune response to arbovirus and respiratory virus infections, vaccine development and anti-viral drug testing.
Acknowledgments
Our sincere thanks to all participants in this study.
We also thank Bassam Hallis, Alex Sigal, and Tulio de Oliveira of BEI resources of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, who provided SARS-CoV-2 Wild-type strain, and Alpha and Beta variants. Research was supported by NIH/NIAID award no. U01AI151797 and National Research Council of Thailand award no. N35A640037.
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award no. U01AI151797). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was also partially funded by National Research Council of Thailand under Award Number N35A640037.
Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation or publication. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70–25.
References
- Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–80. DOIPubMedGoogle Scholar
- Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac—PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853. DOIPubMedGoogle Scholar
- Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385:875–84. DOIPubMedGoogle Scholar
- Wang GL, Wang ZY, Duan LJ, Meng QC, Jiang MD, Cao J, et al. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N Engl J Med. 2021;384:2354–6. DOIPubMedGoogle Scholar
- Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35–45. DOIPubMedGoogle Scholar
Figure
Table
Cite This ArticleOriginal Publication Date: September 24, 2021
Table of Contents – Volume 27, Number 12—December 2021
| EID Search Options |
|---|
|
|
|
|
|
|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Opass Putcharoen, Emerging Infectious Diseases Clinical Center, Thai Red Cross, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Top